On Friday, Nektar Therapeutics (NASDAQ: NKTR) opened higher 3.96% from the last session, before settling in for the closing price of $1.01. Price fluctuations for NKTR have ranged from $0.42 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.42%. Company’s average yearly earnings per share was noted 49.34% at the time writing. With a float of $178.21 million, this company’s outstanding shares have now reached $191.38 million.
Considering the fact that the conglomerate employs 137 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 67.8%, operating margin of -145.96%, and the pretax margin is -180.71%.
Nektar Therapeutics (NKTR) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nektar Therapeutics is 3.41%, while institutional ownership is 74.37%. The most recent insider transaction that took place on Nov 19 ’24, was worth 7,863. In this transaction Chief R&D Officer of this company sold 7,785 shares at a rate of $1.01, taking the stock ownership to the 243,019 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Chief Legal Officer sold 6,407 for $1.01, making the entire transaction worth $6,471. This insider now owns 218,856 shares in total.
Nektar Therapeutics (NKTR) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.22 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.2) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.34% per share during the next fiscal year.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Check out the current performance indicators for Nektar Therapeutics (NKTR). In the past quarter, the stock posted a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.75 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Compared to the last year’s volume of 1.77 million, its volume of 2.09 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 10.60%. Additionally, its Average True Range was 0.09.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 13.09%, which indicates a significant decrease from 14.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.55% in the past 14 days, which was lower than the 67.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2720, while its 200-day Moving Average is $1.2369. Nevertheless, the first resistance level for the watch stands at $1.1033 in the near term. At $1.1567, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2033. If the price goes on to break the first support level at $1.0033, it is likely to go to the next support level at $0.9567. Should the price break the second support level, the third support level stands at $0.9033.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
There are currently 184,458K shares outstanding in the company with a market cap of 201.35 million. Presently, the company’s annual sales total 90,120 K according to its annual income of -276,060 K. Last quarter, the company’s sales amounted to 24,120 K and its income totaled -37,060 K.
